Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5471 - Overweight, obesity and weight gain after breast cancer (BC): a prospective clinical study


22 Oct 2018


Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care


Survivorship;  Supportive and Palliative Care

Tumour Site

Breast Cancer


Antonio Di Meglio


Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300


A. Di Meglio1, M. El-Mouhebb1, S. Michiels2, L. Jones3, M. Annonay4, A. Zingarello5, M. Matias1, S. Everhard6, A.L. Martin7, P. Arveux8, O. Tredan9, P. Soulie10, P.H. Cottu11, A.H. Partridge12, L. Del Mastro13, J.A. Ligibel14, F. André1, I. Vaz-Luis1

Author affiliations

  • 1 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 2 Team Oncostat, Cesp, Gustave Roussy, 94805 - Villejuif/FR
  • 3 Exercise Oncology Research Program, Memorial Sloan Kettering Cancer Center, New York/US
  • 4 972, Institute Bergonié, 33076 - Bordeaux/FR
  • 5 Inserm Umr 981, Gustave Roussy, Université Paris-Saclay, 94800 - Villejuif/FR
  • 6 Ucbg, UNICANCER, 75654 - Paris/FR
  • 7 Research & Develpment, Unicancer, 75654 - Paris/FR
  • 8 Medical Oncology, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 9 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 10 Medical Oncology, Centre Paul Papin, 49055 - Angers/FR
  • 11 Medical Oncology, Institut Curie, 75248 cedex5 - Paris/FR
  • 12 Medical Oncology, Dana-Farber Cancer Institute, MA 02215, - Boston/US
  • 13 Medical Oncology, Ospedale Policlinico San Martino, 16132 - Genova/IT
  • 14 Medical Oncology, Dana-Farber Cancer Institute, Boston/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5471


Overweight and obesity are a growing health problem worldwide and are linked to poor quality of life and BC outcomes. Fewer data are available that describe patterns of weight change or evaluate robust associations with weight gain following BC in a European population.


We used data collected from 4875 women with Stage I-III BC included in an ongoing prospective French multicenter clinical study from 2012-14 (CANTO, NCT01993498). Body Mass Index (BMI) and physical activity (PA) were assessed at diagnosis (dx), 3-6 (T1) and 12 (T2) months after primary treatment. Weight changes ≥ 5% of weight at dx were considered significant. Group based trajectory models (GBTM) described risk of overweight or obesity over time. Multivariate logistic regression assessed factors associated with significant weight gain at T1 and T2.


At dx, mean age was 56 y (range 22-88), median BMI was 24.6 (range 14.7-59.0), 29% pts were overweight and 19% obese. 54% pts received chemo (CT) and 82% endocrine therapy (ET). GBTM found that the majority of overweight and obese pts remained so over time. By T2, weight increased in 24% pts (median gain + 5 Kg [range 2-33]), was stable in 63% pts and decreased in 13% pts in the overall population. Factors associated with higher risk of significant weight gain by T2 included age <50 vs > 65 (adjusted odds ratio 2.1 [95% Confidence Interval 1.3-3.2]), receipt of CT vs no (1.6 [1.3-2.1]), receipt of ET vs no (1.7 [1.1-2.7]), PA < 10 MET-hours/week vs ≥ (1.3 [1.1-1.6]) and having already gained weight by T1 (for each Kg gained, 1.6 [1.5-1.6]) (Table).Table: 1738P

Multivariate logistic regression of factors associated with weight gain after BC in the overall population (N = 4875)

T1 (3-6 months after treatment)T2 (12 months after treatment)
% pts who gained weightaOR* (95% CI)% pts who gained weightaOR* (95% CI)
Age (years) <50 50-65 >6525 17 82.8 (1.8-4.2) 2.2 (1.6-3.0) ref35 24 112.1 (1.3-3.2) 2.0 (1.5-2.7) ref
BMI at diagnosis (kg/m2) Underweight (<18.5) Normal (18.5-24.9) Overweight (25.0-29.9) Obese (≥30)25 18 16 141.7 (0.9-3.0) 1.3 (1.1-1.7) 1.4 (1.1-1.9) ref33 26 24 181.9 (1.1-3.4) 1.7 (1.2-2.3) 1.7 (1.3-2.4) ref
Level of Physical Activity^ Failing to reach 10 Reach/maintain ≥1016 171.0 (0.8-1.2) ref26 221.3 (1.1-1.6) ref
Receipt of chemotherapy Yes No21 121.3 (1.1-1.7) ref29 181.6 (1.3-2.1) ref
Receipt of endocrine therapy Yes No16 191.1 (0.7-1.5) ref24 251.7 (1.1-2.7) ref
Weight gain at T1 Continuous, for 1 Kg gained---1.6 (1.5-1.6)

aOR= adjusted odds ratio; CI= confidence interval.


Adjusted for all variables in the table + menopausal status, education, smoking status, alcohol, tumor stage, subtype, breast and axillary surgery. ^In Metabolic Equivalent of Task (MET)-hours/week, based on World Health Organization recommendations on physical activity and expressed as change in physical activity behavior from diagnosis to T1 and to T2, respectively.


In this large contemporary epidemiology study of French BC survivors, a significant proportion of pts were overweight or obese at dx, and one in four of all pts gained substantial weight after treatment. Weight gain is particularly common in pts who are younger, treated with CT or ET and less physically active. Our data will inform weight loss survivorship programs targeting pts at higher risk of overweight, obesity and weight gain after BC.

Clinical trial identification


Legal entity responsible for the study



Has not received any funding.

Editorial Acknowledgement


A. Di Meglio: Recipient of the 2017 ESMO Clinical research Fellowship Award. I. Vaz-Luis: Recipient of research grants from Susan Komen for the Cure and the “Association pour la recherche sur le cancer (ARC)”. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.